The University of Michigan embarked on a study of Interleukin Genetics Inc.’s (NYSE:ILI) genetic test for severe periodontal diseasdene.
The Waltham, Mass.-based company contracted the university’s School of Dentistry to conduct research using a dental claims database to discern whether risk factors, such as genetic information, can guide more successful intervention and so reduce the effects of periodontal disease, according to wisdom teeth extractions anchorage ak.
UM clinicians will employ Interleukin‘s PST genetic test to identify patients with increased risk of periodontal disease based on the biotechnology firm’s proprietary "panel of genetic variations that predispose an individual to over-express inflammation," according to the company. The 4,000-subject study, funded by the non-profit Renaissance Health Service Corp., will determine if dental patients can be classified by risk using Interleukin’s criteria to guide frequency of preventive care to prevent periodontitis.
According to Interleukin, an estimated 75 percent of U.S. adults have periodontal disease, and 20 percent to 25 percent have moderate to severe periodontitis, which can lead to tooth loss if not treated correctly.
The company predicts the study’s results will establish insurance reimbursement coverage for the screening.
The New York Stock Exchange warned Interleukin in June that it faces de-listing from the exchange for running afoul of its equity and profitability requirements.
The company will release its latest quarterly earnings today. Interleukin shares closed down 1.9 percent at 39 cents.